DaVita Inc. (DVA) Down 5.6% — Should I Dissolve This Stake?
DaVita Inc. (DVA) closed at $183.09 on the NYSE this Thursday, shedding 5.56% and giving back $10.77 from Wednesday's close of $193.86. The session's decline was sharp enough to push shares below the 50-day moving average of $201.51 and toward the 200-day average of $186.53—a technically significant deterioration that will draw attention from chart-focused investors. At current levels, DVA sits roughly 26% below its 52-week high of $247.49, reached on August 3, 2026, underscoring how much ground the stock has ceded since that peak.
Volume came in at approximately 1.37 million shares, running well above the 90-day average of roughly 826,000—a notable pickup in turnover that accompanied the decline. The elevated volume on a down day adds some weight to the selling pressure, suggesting broader participation in Thursday's retreat rather than a quiet drift lower.
Why DaVita Inc. Price is Moving Lower
Thursday's decline looks less like a response to fresh bad news and more like a natural unwinding of a swift, crowded rally. DVA had surged 10.06% between September 1 and September 16, carried higher in part by a 4.28% jump on September 14 alone, when investors focused on DaVita's 2026 EPS guidance of $14.10–$15.20—a range that sits above the $14.57 analyst consensus. That guidance-driven enthusiasm pulled buyers in quickly, and Thursday's 5.59% reversal to $183.02 (with an intraday low of $184.18) reflects profit-taking and technical selling after the stock ran hard in a short window. The move below the 50-day moving average of $201.51 and the proximity to the 200-day average of $186.53 add a technical dimension to the selling, as momentum traders and systematic strategies often treat those crossings as exit signals.
The fundamental backdrop from DaVita's most recent quarter is genuinely constructive, which makes Thursday's pullback look more like positioning noise than a verdict on the business. In early August, the company posted adjusted EPS of $4.02 against a $3.88 consensus estimate, and revenue of $3.554 billion edged past the $3.50 billion expected—a 5.2% year-over-year increase. EPS improved dramatically from $2.95 a year earlier, reinforcing that earnings momentum is real. One area worth monitoring, however, is revenue per treatment, which slipped to $415.87 from $417.59 sequentially—a modest but directionally relevant softening that could attract scrutiny if it persists into future quarters.
The broader picture, then, is a stock that ran aggressively on strong guidance and is now consolidating from an overstretched position. With shares having climbed more than 10% in just over two weeks before Thursday's reversal, some degree of mean-reversion was not unexpected. The question for investors now is whether the 200-day moving average near $186.53 provides a floor, or whether the technical damage from breaching the 50-day encourages a deeper reset.
What is the DaVita Inc. Rating - Should I Sell?
Weiss Ratings assigns DVA a B- rating. Current recommendation is Buy.
That B- rating reflects a business with genuine underlying strength, even if the stock's current technical posture gives investors reason for pause. Revenue growth of 5.17% and a profit margin of 6.04% are the headline fundamentals, and together they support the Excellent Growth Index—a notable designation for a dialysis services provider operating in a heavily regulated, cost-intensive environment where consistent top-line expansion is not easily taken for granted. The 6.04% margin is characteristic of the reimbursement-driven economics of kidney care, where pricing is substantially governed by Medicare and Medicaid rates rather than market dynamics.
Efficiency is where DaVita stands out most sharply. An ROE of 88.48% earns the Good Efficiency Index—an extraordinary figure that reflects how aggressively the company has leveraged its equity base, partly a function of share buybacks that have meaningfully reduced the denominator over time. The Good Solvency Index signals that the balance sheet, while carrying meaningful debt as is common for operators in this space, is not flashing acute distress. The Good Total Return Index adds further support for performance-oriented investors, suggesting that over longer measurement periods, DVA has rewarded shareholders adequately relative to its risk profile.
The Fair Volatility Index is the one sub-index that warrants honest attention today. Thursday's 5.56% single-session decline—on top of a 10% rally that evaporated in part within one trading day—is precisely the kind of swing the Fair Volatility designation anticipates. Investors with lower tolerance for sharp drawdowns should weigh that dynamic carefully before adding exposure at current levels. A forward P/E of 15.86 is relatively modest and arguably reflects the market pricing in execution risk around the $14.10–$15.20 EPS guidance range rather than assuming a best-case outcome.
Within the Health Care sector, DaVita is on equal footing with CVS Health Corporation (CVS, B-) and Cencora, Inc. (COR, B-), while trailing McKesson Corporation (MCK, B), Cardinal Health, Inc. (CAH, B), and Quest Diagnostics Incorporated (DGX, A-). That relative positioning suggests DaVita is a credible Buy-rated name in Health Care, but investors have stronger-rated alternatives available if they want to reduce single-stock risk during a period of technical weakness.
About DaVita Inc.
DaVita Inc. (DVA) is a Health Care company focused almost exclusively on providing kidney care services to patients suffering from chronic kidney disease and end-stage renal disease. The company is one of the largest providers of dialysis services in the United States, operating an extensive network of outpatient dialysis centers that deliver life-sustaining treatment to patients who require it multiple times per week. Its scale—spanning hundreds of clinics and tens of thousands of patients—creates significant operational leverage and positions the company as a critical infrastructure provider within the renal care ecosystem.
DaVita's business model is built around long-term patient relationships driven by medical necessity, giving it a relatively stable and recurring revenue base that is less susceptible to discretionary spending cycles than many other health care subsectors. The majority of the company's revenue flows through government reimbursement programs, primarily Medicare and Medicaid, which provides predictability but also creates exposure to policy and rate-setting decisions outside management's direct control. Revenue per treatment metrics serve as a key operational indicator, reflecting the blend of reimbursement rates, patient acuity, and treatment mix across its clinic network.
Beyond its domestic operations, DaVita has built an international kidney care presence, extending its clinical model into select markets outside the United States. The company's competitive advantages rest on its established network density, clinical protocols refined over decades, purchasing scale for dialysis supplies and pharmaceuticals, and its ability to recruit and retain specialized nephrology care teams. These structural advantages make DaVita difficult to displace at the point of care and support patient retention rates that are characteristic of a medically essential service rather than a consumer choice.
Investor Outlook
DaVita Inc. (DVA) carries a Weiss Rating of B- (Buy), but Thursday's close below the 50-day moving average and the proximity to the 200-day average of $186.53 make near-term technical behavior an important watch item. Investors should monitor whether the stock stabilizes at current support levels or continues to give back the September rally, while keeping close tabs on any updates to the 2026 EPS guidance range of $14.10–$15.20 and trends in revenue per treatment as the next reporting period approaches. See full rankings of all B--rated Health Care stocks inside the Weiss Stock Screener.
--